|
|
Volumn 102, Issue 24, 2010, Pages 1821-1823
|
|
Pancreatic cancer: will incremental advances begin to make a difference?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
ERLOTINIB;
FLUOROURACIL;
FOLINIC ACID;
GEMCITABINE;
QUINAZOLINE DERIVATIVE;
TUMOR MARKER;
ADJUVANT CHEMOTHERAPY;
DISEASE FREE SURVIVAL;
HUMAN;
METABOLISM;
MORTALITY;
NOTE;
PANCREAS TUMOR;
PATHOLOGY;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SURVIVAL;
TREATMENT FAILURE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHEMOTHERAPY, ADJUVANT;
DEOXYCYTIDINE;
DISEASE-FREE SURVIVAL;
FLUOROURACIL;
HUMANS;
LEUCOVORIN;
PANCREATIC NEOPLASMS;
QUALITY OF LIFE;
QUINAZOLINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SURVIVAL ANALYSIS;
TREATMENT FAILURE;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 79952118674
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq521 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
